Three-yr safety and efficacy of everolimus and low-dose cyclosporine in de novo pediatric kidney transplant patients

Pediatric Transplantation

Volumn 18, Issue 4, 2014, Pages 350-356

  Ferraresso, Mariano ^a,b   Belingheri, Mirco ^c   Ginevri, Fabrizio ^d   Murer, Luisa ^e   Dello Strologo, Luca ^f   Cardillo, Massimo ^c   Parodi, Angelica ^d   Ghirardo, Giulia ^e   Guzzo, Isabella ^f   Innocente, Annalisa ^c   Ghio, Luciana ^c  

^a UNIVERSITY OF MILAN   (Italy)

^b IRCCS MULTIMEDICA   (Italy)

^c FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

^d G GASLINI INSTITUTE   (Italy)

^e UNIVERSITY OF PADOVA   (Italy)

^f BAMBINO GESÙ CHILDREN S HOSPITAL   (Italy)

Author keywords

acute rejection; cyclosporine; donor specific antibodies; everolimus; long term results; pediatric kidney transplantation

Indexed keywords

BASILIXIMAB; CYCLOSPORIN A; EVEROLIMUS; PREDNISONE; CYCLOSPORIN; HYBRID PROTEIN; IMMUNOSUPPRESSIVE AGENT; MONOCLONAL ANTIBODY; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RAPAMYCIN;

ACUTE GRAFT REJECTION; ARTICLE; CATCH UP GROWTH; CHILD; CHRONIC GRAFT REJECTION; CLINICAL ARTICLE; DRUG EFFICACY; DRUG SAFETY; FEMALE; GLOMERULUS FILTRATION RATE; GRAFT SURVIVAL; HUMAN; HUMAN TISSUE; KIDNEY ALLOGRAFT; KIDNEY GRAFT; LYMPHOPROLIFERATIVE DISEASE; MALE; SCHOOL CHILD; ADOLESCENT; ANALOGS AND DERIVATIVES; CLINICAL TRIAL; DRUG ADMINISTRATION; DRUG COMBINATION; GRAFT REJECTION; KAPLAN MEIER METHOD; KIDNEY TRANSPLANTATION; MORTALITY; MULTICENTER STUDY; PRESCHOOL CHILD; PROSPECTIVE STUDY; TREATMENT OUTCOME;

ADOLESCENT; ANTIBODIES, MONOCLONAL; CHILD; CHILD, PRESCHOOL; CYCLOSPORINE; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; GRAFT REJECTION; GRAFT SURVIVAL; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KAPLAN-MEIER ESTIMATE; KIDNEY TRANSPLANTATION; MALE; MYCOPHENOLIC ACID; PREDNISONE; PROSPECTIVE STUDIES; RECOMBINANT FUSION PROTEINS; SIROLIMUS; TREATMENT OUTCOME;

EID: 84900011637     PISSN: 13973142     EISSN: 13993046     Source Type: Journal    
DOI: 10.1111/petr.12261     Document Type: Article

References (28)

1. Magee JC, Krishnan SM, Benfield MR, Hsu DT, Shneider BL,. Pediatric transplantation in the United States, 1997-2006. Am J Transplant 2008: 8: 935-945.
2. Cai J, Terasaki PI,. Induction immunosuppression improves long-term graft and patient outcome in organ transplantation: An analysis of United Network for Organ Sharing registry data. Transplantation 2010: 90: 1511-1515.
3. El-Zoghby ZM, Stegall MD, Lager DJ, et al. Identifying specific causes of kidney allograft loss. Am J Transplant 2009: 9: 527-535.
4. Lamb KE, Lodhi S, Meier-Kriesche HU,. Long-term renal allograft survival in the United States: A critical reappraisal. Am J Transplant 2011: 11: 450-462.
5. Lodhi SA, Lamb KE, Meier-Kriesche HU,. Solid organ allograft survival improvement in the United States: The long-term does not mirror the dramatic short-term success. Am J Transplant 2011: 11: 1226-1235.
6. Cochat P, Harambat J,. Maximizing growth in children after renal transplantation. Transplantation 2009: 88: 1321-1322.
7. Kahan BD, Kaplan B, Lorber MI, Winkler M, Cambon N, Boger RS,. RAD in de novo renal transplantation: Comparison of three doses on the incidence and severity of acute rejection. Transplantation 2001: 71: 1400-1406.
8. Schuler W, Sedrani R, Cottens S, et al. SDZ RAD, a new rapamycin derivative: Pharmacological properties in vitro and in vivo. Transplantation 1997: 64: 36-42.
9. Kovarik JM, Kahan BD, Kaplan B, et al. Longitudinal assessment of everolimus in de novo renal transplant recipients over the first post-transplant year: Pharmacokinetics, exposure-response relationships, and influence on cyclosporine. Clin Pharmacol Ther 2001: 69: 48-56.
10. Schuurman HJ, Cottens S, Fuchs S, et al. SDZ RAD, a new rapamycin derivative: Synergism with cyclosporine. Transplantation 1997: 64: 32-35.
11. Gaumann A, Schlitt HJ, Geissler EK,. Immunosuppression and tumor development in organ transplant recipients: The emerging dualistic role of rapamycin. Transpl Int 2008: 21: 207-217.
12. Baselga J, Campone M, Piccart M, et al. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med 2012: 366: 520-529.
13. Schwartz GJ, Muñoz A, Schneider MF, et al. New equations to estimate GFR in children with CKD. J Am Soc Nephrol 2009: 20: 629-637.
14. Solez K, Colvin RB, Racusen LC, et al. Banff 07 classification of renal allograft pathology: Updates and future directions. Am J Transplant 2008: 8: 753-760.
15. Kuczmarski RJ, Ogden CL, Guo SS, et al. CDC Growth Charts for the United States: Methods and development. Vital Health Stat 11 2000: 2002: 1-190.
16. Offner G, Toenshoff B, Höcker B, et al. Efficacy and safety of basiliximab in pediatric renal transplant patients receiving cyclosporine, mycophenolate mofetil, and steroids. Transplantation 2008: 86: 1241-1248.
17. Grenda R, Watson A, Vondrak K, et al. A prospective, randomized, multicenter trial of tacrolimus-based therapy with or without basiliximab in pediatric renal transplantation. Am J Transplant 2006: 6: 1666-1672.
18. Ferraresso M, Ghio L, Zacchello G, et al. Pharmacokinetic of cyclosporine microemulsion in pediatric kidney recipients receiving a quadruple immunosuppressive regimen: The value of C2 blood levels. Transplantation 2005: 79: 1164-1168.
19. Pape L, Offner G, Kreuzer M, et al. De novo therapy with everolimus, low-dose ciclosporine A, basiliximab and steroid elimination in pediatric kidney transplantation. Am J Transplant 2010: 10: 2349-2354.
20. Pape L, Lehner F, Blume C, Ahlenstiel T,. Pediatric kidney transplantation followed by de novo therapy with everolimus, low-dose cyclosporine A, and steroid elimination: 3-year data. Transplantation 2011: 92: 658-662.
21. Ettenger R, Hoyer PF, Grimm P, et al. Multicenter trial of everolimus in pediatric renal transplant recipients: Results at three years. Pediatr Transplant 2008: 12: 456-463.
22. Grushkin C, Mahan JD, Mange KC, Hexham JM, Ettenger R,. De novo therapy with everolimus and reduced-exposure cyclosporine following pediatric kidney transplantation: A prospective, multicenter, 12-month study. Pediatr Transplant 2013: 17: 237-243.
23. Ginevri F, Nocera A, Comoli P, et al. Posttransplant de novo donor-specific HLA antibodies identify pediatric kidney recipients at risk for late antibody-mediated rejection. Am J Transplant 2012: 12: 3355-3362.
24. Everly MJ, Rebellato LM, Haisch CE, et al. Incidence and impact of de novo donor-specific alloantibody in primary renal allografts. Transplantation 2013: 95: 410-417.
25. Albano L, Berthoux F, Moal MC, et al. Incidence of delayed graft function and wound healing complications after deceased-donor kidney transplantation is not affected by de novo everolimus. Transplantation 2009: 88: 69-76.
26. Chavers BM, Gillingham KJ, Matas AJ,. Complications by age in primary pediatric renal transplant recipients. Pediatr Nephrol 1997: 11: 399-403.
27. Grenda R,. Effects of steroid avoidance and novel protocols on growth in paediatric renal transplant patients. Pediatr Nephrol 2010: 25: 747-752.
28. Cibrik D, Silva HT, Vathsala A, et al. Randomized trial of everolimus-facilitated calcineurin inhibitor minimization over 24 months in renal transplantation. Transplantation 2013: 95: 933-942.